Cell therapy (NK cells) · Kills target cells · developed by Fate Therapeutics
FT500 is an off-the-shelf natural killer cell preparation derived from a clonal induced pluripotent stem cell line. It binds stress-induced ligands on tumor cells, leading to tumor cell lysis, and secretes inflammatory cytokines and chemokines. It is being studied in advanced solid tumors, lymphoma, and several cancers including gastric, colorectal, head and neck, lung, breast, and renal cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03841110 | Phase 1 | Advanced Solid Tumors | Completed | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsColorectal CancerEGFR Positive Solid TumorGastric CancerHead and Neck CancerHepatocellular CarcinomaHER2-positive Breast CancerLymphomaMelanomaNSCLCPancreas CancerRenal Cell CarcinomaSmall Cell Lung CancerSquamous Cell Carcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →